Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — 2025 J.P. Morgan Healthcare Conference
26 slides from Wuxi Apptec Co., Ltd. Class A's conference presentation, Jan 15, 2025
Slide 1: WuXi AppTec 2025 J.P. Morgan Healthcare Conference
WuXi AppTec 2 0 2 5 J . P. M o r g a n H e a l t h c a r e C o n f e r e n c e January 15, 2025 1 603259.SH / 2359.HK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Agenda
01 Company Overview 02 Business Highlights 03 Financial Performance 04 Company Outlook 3 Note: All financials disclosed in this presentation are prepared based on International Financial Reporting Standards (or “IFRSs”). The currency is RMB. All net profit disclosed in this presentation represents n
Slide 4: 1. Company Overview
1. Company Overview ze S| od
Slide 5: With Customers as our Top Priority, Demand for Integrated CRDMO Services Continues to Grow
With Customers as our Top Priority, Demand for Our Integrated CRDMO Services Continues to Grow Despite External Challenges Our Vision “Every drug can be made and Biotech Companies every disease can be treated” Quality Speed Large Pharmas through building the open-access platform with the most compre
Slide 6: Focused on Delivering Value to Customers as Leading Global CRDMO Company
Focused on Delivering Value to Customers as Leading Global CRDMO Company 6,000+ 38,000+ 32 Active Customers1 Total Employees1 Global Sites in 9 Countries1 >3,300 18% 41,000L # of Molecules in Small of Small Molecule New Drugs Solid Phase Peptide Synthesizer Molecule CDMO Pipeline1 Approved by FDA 20
Slide 7: Continuously Enhance Capabilities and Capacity to Support Future Growth
Continuously Enhance Capabilities and Capacity to Support Future Growth Accelerate Global CRDMO Capacity Expansion to Better Meet Growing Customer Demand Changshu Wuxi Nantong Tianjin Munich Changzhou Minnesota Boston Suzhou Couvet New Jersey Delaware Taixing San Diego Chengdu Nanjing Shanghai Wuhan
Slide 8: Actively Promoting Sustainability and Enhancing Global ESG Leadership
Actively Promoting Sustainability and Enhancing Global ESG Leadership Consecutive Four Years’ MSCI “AA” Rating and S&P Global DJSI Member; Improved to EcoVadis “Gold” Rating in 2024 Named to S&P Global Joined the United Nations Consecutive “AA” ratings Improved to “Gold” rating DJSI consecutively in
Slide 9: Unwavering Commitment to Customer IP Protection and the Highest Quality & Compliance Standards
Unwavering Commitment to Customer IP Protection and the Highest Quality & Compliance Standards 404 1 38 Quality Audits & Information Security Inspections by Global Audits by Global Customers and Regulatory Customers in H1 2024, Authorities in H1 2024 with 0 Critical Findings 2 100% 24 Pass Rate with
Slide 10: 2. Business Highlights
2. Business Highlights Z ls Ban. =|
Slide 11: Integrated Research Platform with WuXi Chemistry, WuXi Biology & WuXi Testing
Integrated Research Platform with WuXi Chemistry, WuXi Biology & WuXi Testing in Collaboration to Enable Innovation from Early Discovery Stage WuXi Chemistry - Drug Discovery Design Analyze Deliver PCC1 Enable IND1 Discover Targets Develop & Run Assays Demonstrate Efficacy Prepare for FIH1 Study WuX
Slide 12: Building Capability at Innovation Forefront and Enabling CRDMO Business Model
Building Capability at Innovation Forefront and Enabling CRDMO Business Model 2014 2015 2016 2019 2020 2021 2022 2023 2024 BsAb ADC/ Cancer Fusion Oligo/ASO TIL Target Protein CAR-T/Cell AAV/Gene mRNA Gene Oncolytic Covalent OBOC Single Cell & AOC/ DEL RNA DAC PDC Vaccine Protein /siRNA Degradation
Slide 13: WuXi Chemistry: Growing Small Molecule CRDMO Pipeline Driven by Follow the Molecule + Win the Molecule
WuXi Chemistry: Growing Small Molecule CRDMO Pipeline Driven by “Follow the Molecule + Win the Molecule” Strategies “R” 7%↑ 450,000+ 14,751 compounds Compounds 1 Q1-Q3 2024 Newly 2682 Added Molecules to D&M Pipeline 898 in Total 915 2,852 Preclinical & Phase 1 3 762 16% of Global Clinical 14 Stage N
Slide 14: Small Molecule D&M: Expansion of Phase III & Commercial Pipeline Continues to Drive Strong Growth
Small Molecule D&M: Expansion of Phase III & Commercial Pipeline Continues to Drive Strong Growth # of Small Molecule Phase III Revenue from Small Molecule & Commercial Drugs Phase III & Commercial Drugs1 # of Molecules RMB Billion Phase III Commercial >100% +37% 9.0 147 127 107 68 61 4.6 50 H1 66 7
Slide 15: Produce 4 out of 10 Best-selling Small Molecule Drugs in 2023
Produce 4 out of 10 Best-selling Small Molecule Drugs in 2023 $30+ billion combined global sales of these 4 drugs in 2023 15 Source: Top Small Molecule Products by Retail Sales in 2023 Complied by Evaluate Pharma.
Slide 16: Produce 6 out of 31 Small Molecules Approved by US FDA in 2024
Produce 6 out of 31 Small Molecules Approved by US FDA in 2024 US FDA New Drug Approvals by Modality (2024) Peptide Oligonucleotide 2% 3% Cell & Gene Therapy 12 11% 7 Small molecule 52% 31 Produced 19% of new drugs 19 approved in 2024 Biologics 32% 16 Source: FDA (CDER & CBER); internal analysis. Th
Slide 17: Producing the Industry's Most Impactful New Therapies
Producing the Industry’s Most Impactful New Therapies OUT OF 2023 Molecules of the Year Nominees “We asked our readers and reviewers to nominate molecules for our annual Molecule of the Year spot based on what you found most technically impressive and impactful. These top 10 finalists are selected b
Slide 18: Capturing Fast Growing GLP-1 Agonists Market
Capturing Fast Growing Glucagon-Like Peptide-1 Agonists (GLP-1) Market WuXi Chemistry GLP-1 Pipeline Growth is Outpacing the Industry 不同疫苗在防护率上的差异 Clinical Stage 9 out of 47 M-RNA疫苗相比传统疫苗在预防新 型冠状病毒感染方面表现更为突出 Peptide Drugs Global clinical stage GLP-1 synthetic drug pipeline (small molecule & peptide)
Slide 19: TIDES (Oligo & Peptide): Enhancing Capabilities and Fast Growing Capacity
TIDES (Oligo & Peptide): Enhancing Capabilities and Fast Growing Capacity to Bring the Next Wave of Accelerated Growth TIDES Revenue Solid Phase Peptide Synthesizer Total Reactor Volume RMB Billion Liter >100,000 >60% 3.4 41,000 32,000 2.0 Q1-Q3 0.8 3.5 0.3 4,000 6,000 500 2,000 2020 2021 2022 2023
Slide 20: 3. Financial Performance
3. Financial Performance 20
Slide 21: Navigating Through Cycles with Continued Growth in Revenue and Profitability
Navigating Through Cycles with Continued Growth in Revenue and Profitability Revenue Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company RMB Billion RMB Billion Excluding COVID-19 Commercial Project Adjusted Non-IFRS NPM% COVID-19 Commercial Project CAGR >25% 17.6% 18.0% 22.0% 22.
Slide 22: Boosting D&M Orders and Enhancing Future Growth Visibility Through CRDMO
Boosting D&M Orders and Enhancing Future Growth Visibility Through CRDMO Total Backlog Growing 35% CAGR 2018-Q3 2024, with D&M Backlog Surging at 55% CAGR; 2x “R” Orders Amplified to 12x “D&M” Orders in the Same Period RMB Billion Backlog excluding COVID-19 Commercial Project COVID-19 Commercial Pro
Slide 23: Sustained Positive Free Cash Flow Driven by Business Growth and Operating Efficiency
Sustained Positive Free Cash Flow Driven by Business Growth and Operating Efficiency Improvement Continued Strong Operating Cash Flow to Invest in Capabilities & Capacity & Talents; D&M Capex to Double in 2025 RMB Billion Capex1 12.6 Operating Cash Flow COVID-19 Commercial Project 10.0 10.2 9.8 8.1
Slide 24: Enabling Value Creation and Consistent Shareholder Returns
Enabling Value Creation and Consistent Shareholder Returns Basic Earnings per Share (EPS)1 Dividends & Share Buybacks Continue to Improve Through Cycles ~70% of Adjusted Non-IFRS Net Profit in 2024 RMB RMB Billion Dividends Declared & Paid Share Buybacks for Cancellation 8 x4.8 7.1 7 3.5 3.3 3.0 6 3
Slide 25: 4. Growth Outlook
4. Growth Outlook i ls Be 3)
Slide 26: Our Unique CRDMO Business Model Positions the Company to Continue Growth
Our Unique CRDMO Business Model Positions the Company to Continue Growth in Both Good and Challenging Times Our unique integrated CRDMO business model can effectively meet the growing demand of customers worldwide. It enables the Company to closely follow scientific innovations, develop 1 distinct i